The cytoprotective role of gemcitabine-induced autophagy associated with apoptosis inhibition in triple-negative MDA-MB-231 breast cancer cells

29Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

Abstract

Triple-negative breast cancer (TNBC), which is estrogen receptor (ER)-negative, progesterone receptor-negative and is also negative for HER2 expression, remains a great clinical challenge due to its strong resistance to chemotherapy at the late stage of treatment and relatively unfavorable prognosis. Gemcitabine has been approved by the FDA/SFDA for use as a first-line therapeutic drug against advanced or metastatic breast cancer. Therefore, the clarification of the mechanisms underlying gemcitabine-acquired resistance is of particular importance for the optimal management of TNBC. A number of studies have revealed that autophagy, which has been found to protect cancer cells from anti-cancer drug-induced death, may contribute to the development of drug resistance. However, the association between autophagy and gemcitabine treatment in TNBC cells has yet to be defined. Our study clearly demonstrates that gemcitabine is able to induce mTOR-independent autophagy in human triple-negative MDA-MB-231 breast cancer cells. In addition, we demonstrate that autophagy protects MDA-MB-231 cells from gemcitabine-induced cell growth inhibition and apoptosis, indicating that gemcitabine can activate autophagy to impair the sensitivity of MDA-MB-231 cells. Furthermore, as shown by our results, the inhibition of gemcitabine-induced autophagy by chloroquine shifts the expression of the p53 protein, Bcl-2 family proteins and the relative Bax/Bcl-xL ratio in favor of promoting apoptosis. These results reveal that the inhibition of apoptosis may be one of the mechanisms of autophagy-induced cytoprotection in gemcitabine-treated MDA-MB-231 cells. The apoptotic and autophagic processes constitute a mutual inhibition system and jointly seal the fate of TNBC cells that are exposed to gemcitabine. Thus, our study suggests that the combination of an autophagic inhibitor and gemcitabine as a therapeutic strategy may represent a promising approach with greater clinical efficacy for patients with TNBC. However, extended preclinical trials are required to further determine the positive effects of the inhibition of autophagy on the efficacy of gemcitabine.

References Powered by Scopus

Cancer statistics, 2013

11919Citations
N/AReaders
Get full text

Autophagy: Renovation of cells and tissues

5143Citations
N/AReaders
Get full text

Triple-negative breast cancer: Clinical features and patterns of recurrence

3994Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Regulation of multidrug resistance by microRNAs in anti-cancer therapy

160Citations
N/AReaders
Get full text

Identification of DHODH as a therapeutic target in small cell lung cancer

99Citations
N/AReaders
Get full text

Molecular mechanisms underlying autophagy-mediated treatment resistance in cancer

72Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Chen, M., He, M., Song, Y., Chen, L., Xiao, P., Wan, X., … Shen, P. (2014). The cytoprotective role of gemcitabine-induced autophagy associated with apoptosis inhibition in triple-negative MDA-MB-231 breast cancer cells. International Journal of Molecular Medicine, 34(1), 276–282. https://doi.org/10.3892/ijmm.2014.1772

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 13

62%

Researcher 7

33%

Professor / Associate Prof. 1

5%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 8

40%

Medicine and Dentistry 7

35%

Agricultural and Biological Sciences 4

20%

Pharmacology, Toxicology and Pharmaceut... 1

5%

Save time finding and organizing research with Mendeley

Sign up for free